GEN Exclusives

More »

GEN Poll

More »
Apr 22, 2014

Megamerger Dealzapoppin Poll

You can’t tell the players without a scorecard, especially in biopharma. This week alone, AstraZeneca reportedly turned down a £60 billion ($101 billion) offer from Pfizer, while Novartis, GlaxoSmithKline, and Eli Lilly agreed to overhaul themselves in a series of deals totaling $28.5 billion. Also, Valeant Pharmaceuticals International made a hostile $45.7 billion bid for Botox maker Allergan supported by Allergan’s largest shareholder, investor William Ackman’s Pershing Square Capital Management.

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?

Bristol-Myers Squibb
 
  17.5%
Johnson & Johnson
 
  15.1%
Merck & Co.
 
  23.0%
Roche
 
  14.3%
Sanofi
 
  12.7%
Another company
 
  17.5%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?